QLT Plans XR9576 NDA Filing in 2005 After In-Licensing Deal With Xenova
Executive Summary
QLT plans to seek a first-line indication for Xenova's cancer multi-drug resistance agent XR9576 in non-small cell lung cancer with a planned 2005 NDA filing.
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PS038379
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
PS038379
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.